Cancer Cell Detection Technology Wins Kaye Award For Hebrew University ResearchersJune 20, 2004A unique technology for optoelectronic detection of the presence of cancer cells has been developed at the Hebrew University of Jerusalem by a team of researchers headed by Itamar Willner, Enrique Berman Professor of Solar Energy at the Institute of Chemistry. The technology detects the presence of telomerase, an active enzyme appearing in cancer cells that is considered a general marker for different types of cancers. For their work in development of this technology, the research team has been chosen as one of the winners of a Kaye Innovation Award, presented during the Hebrew University's 67th meeting of the Board of Governors. Working with Prof. Willner on this project have been Dr. Eugenii Katz, Dr. Fernando Patolsky and Yossi Weizmann. The technology developed by the researchers works as follows: When chemically-modified magnetic particles are brought into contact with cancer cell samples, the telomerase performs on the magnetic particles the same bioprocess that has occurred in the cancer cells; that is, there is a buildup on the magnetic particles of nucleic acids called telomers. In this process, however, a chemically-modified nucleotide base is incorporated into the telomers. The modified magnetic particles are then separated from the cancer cell sample, and the incorporated material is used to bind a second enzyme that leads to the formation of light by the system. When this happens, it is an indication that cancer was detected on the particles. The method is highly sensitive, indicating the presence of even miniscule numbers of cancer cells in pathological samples. It has been successfully applied thus far to detect a variety of cancers in tissues and body fluids. The technology has provided a basis for the formation of a joint venture company involving the university's Yissum Technology Transfer Company and an Australian company. Under development through this joint venture is a diagnostic kit for the detection of cancer cells in urine samples. Further development is also expected to lead to kits for detecting colon cancer and leukemia in stool and blood samples, respectively. The Kaye Innovation Awards have been given annually since 1994. Isaac Kaye of England, a prominent industrialist in the pharmaceutical industry, established the awards to encourage faculty, staff, and students of the Hebrew University to develop innovative methods and inventions with good commercial potential which will benefit the university and society. | |||||||||||||||||||||
|
Related Cancer Cells News Articles Atomic structure of the mammalian 'fatty acid factory' determined Mammalian fatty acid synthase is one of the most complex molecular synthetic machines in human cells. It is also a promising target for the development of anti-cancer and anti-obesity drugs and the treatment of metabolic disorders. M. D. Anderson study finds change in HER2 status after treatment with Herceptin Researchers at The University of Texas M. D. Anderson Cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. NC State Is First University in Nation to Offer Canine Bone Marrow Transplants Dogs suffering from lymphoma will be able to receive the same type of medical treatment as their human counterparts, as North Carolina State University becomes the first university in the nation to offer canine bone marrow transplants in a clinical setting. DNA editing tool flips its target Imagine having to copy an entire book by hand without missing a comma. Our cells face a similar task every time they divide. They must duplicate both their DNA and a subtle pattern of punctuation-like modifications on the DNA known as methylation. New nano device detects immune system cell signaling Scientists have detected previously unnoticed chemical signals that individual cells in the immune system use to communicate with each other over short distances. VCU Massey Cancer Center Spearheads Novel Clinical Study for Lymphoma Patients The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma. Too much calcium in blood may increase risk of fatal prostate cancer Men who have too much calcium in their bloodstreams may have an increased risk of fatal prostate cancer, according to a new analysis from Wake Forest University School of Medicine and the University of Wisconsin. New role for Natural Killers! Scientists at the University of York have discovered a new role for a population of white blood cells, which may lead to improved treatments for chronic infections and cancer. Variation of normal protein could be key to resistance to common cancer drug Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug. Normalizing tumor vessels to improve cancer therapy Chemotherapy drugs often never reach the tumors they're intended to treat, and radiation therapy is not always effective, because the blood vessels feeding the tumors are abnormal-"leaky and twisty" in the words of the late Judah Folkman, MD, founder of the Vascular Biology program at Children's Hospital Boston. More Cancer Cells News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||